BioCentury | Jun 27, 2011
Clinical News

MDX-1097: Phase II ongoing

...Australia Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: MDX-1097 Business: Cancer Molecular target: Kappa myeloma antigen (KMA...
BioCentury | Apr 27, 2009
Clinical News

MDX-1097: Phase I started

...Ultimo, Australia Medarex Inc. (NASDAQ:MEDX), Princeton, N.J. Product: MDX-1097 Business: Cancer Molecular target: Kappa myeloma antigen (KMA...
BioCentury | Oct 31, 2005
Finance

Ebb & Flow

...is planning a Phase I/IIa trial of its cKap antibody.The chimeric monoclonal antibody targets kappa myeloma antigen (KMA...
Items per page:
1 - 3 of 3